Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Melinda Brown, a director at Precision BioSciences Inc . (NASDAQ:DTIL), recently increased her stake in the company. According to a recent SEC filing, Brown purchased 1,839 shares of common stock on March 26 at a price of $4.75 per share, amounting to a total investment of $8,735. The purchase comes as the stock trades near $4.54, down significantly from its 52-week high of $15.97. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment. Following this transaction, Brown now holds a total of 9,057 shares directly. This purchase reflects a continued interest in the company’s future prospects, despite InvestingPro data indicating analysts expect sales to decline in the current year. The company maintains a solid gross profit margin of 100% and trades at an attractive P/B ratio of 0.54, though investors should note that additional insights are available through InvestingPro’s comprehensive analysis tools.
In other recent news, Precision BioSciences has announced promising developments in its gene editing programs. The company reported initial data from its Phase 1 ELIMINATE-B trial for PBGENE-HBV, a therapy targeting chronic hepatitis B. The trial, which has now expanded to the United States following FDA clearance, showed substantial antiviral activity and a favorable safety profile at the lowest dose level. In a related development, Precision BioSciences received an upgrade from BMO Capital, with analyst Kostas Biliouris raising the rating to Outperform and setting a price target of $34.00, citing the promising nature of their gene editing results.
Additionally, Precision BioSciences presented preclinical data for PBGENE-DMD, a therapeutic candidate for Duchenne muscular dystrophy, at a recent conference. H.C. Wainwright reaffirmed its Buy rating and $60 price target, expressing confidence in the data’s potential to advance into clinical trials. Furthermore, Precision BioSciences announced the retirement of Dr. Sam Wadsworth from its Board of Directors, a change reported in the company’s SEC filings without any noted impact on its strategic direction. These recent developments highlight the company’s ongoing efforts in advancing gene editing therapies for serious genetic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.